Medication-related osteonecrosis of the jaw is an adverse effect of antiresorptive drugs, characterized by the presence of necrotic bone in the maxillofacial area, with or without bone exposure, which does not heal in 8 weeks in patients without oral cancer and without having received radiotherapy in the craniofacial region. There are different factors that increase the risk of developing this pathology, and its diagnosis is based on categorizing the lesion into four stages according to its progression Although there is no standard treatment reported in the literature for medication-related osteonecrosis of the jaws, AAOMS in its latest update in 2022, describe that the main therapeutic objective is to eliminate the pain, control the infection and prevent the progression and occurrence of bone necrosis, maintain or improve the quality of life . This had led to researchers an physicians to seek new adjuvant therapeutic alternatives to conservative and surgical treatment, which can be found reported on the literature the use of hyperbaric oxygen, laser therapy, platelet concentrates, ozone and anabolic agents such as teriparatide and recombinant human bone morphogenetic protein, antioxidants as vitamin E and pentoxifylline in order to improve the prognosis and quality of life of the patients. In the present review results manually extracted from the articles indexed in the PUBMED and SCOPUS databases that respond to de search for the terms: medication-related osteonecrosis of the jaw, treatment and oral surgery, were used, with the aim of describing the emerging treatments for medication-related osteonecrosis of the jaws, discussing the different therapeutic approaches described.